All In Biotech

Drug Trial Radar · NCT07474636

Efficacy and Safety Study of HS-10542 for IgA Nephropathy

A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Dose-Ranging Study to Evaluate the Efficacy and Safety of HS-10542 Capsules in Primary Immunoglobulin A (IgA) Nephropathy

Last checked: Nov 19, 2026Latest source record: Mar 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

90

Planned (sponsor's estimate)

Start

Mar 17, 2026

Primary completion

Dec 10, 2027

Study completion Jan 30, 2028

Sponsor

Sponsor type
Industry
First posted
Mar 16, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 74 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multicenter, randomized, double-blind, parallel, placebo-controlled study and is being conducted to evaluate the efficacy and safety of HS-10542 capsules for primary IgA nephropathy.

Conditions

  • IgAN
  • Immunoglobulin A Nephropathy (IgAN)
  • Glomerular Disease

Interventions

  • HS-10542 High DoseDrug

    Drug: HS-10542 High Dose, QD

  • HS-10542 Low DoseDrug

    Drug: HS-10542 Low Dose, QD

  • PlaceboDrug

    Placebo, QD

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Ratio to baseline in Urine Protein to Creatinine Ratio (sampled from 24h urine collection)Time frame: Baseline and Week 12

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Peking University First Hospital

    Beijing, Beijing Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.